French pharma major Sanofi (Euronext: SAN) announced on Friday that its Insulin aspart Sanofi (insulin aspart 100 Units/mL) has received European Union marketing authorization, and will provide another treatment option for adults, adolescents and children aged one year and older who have diabetes.
The decision follows recent positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), and rounds out Sanofi’s comprehensive insulin portfolio which already includes two rapid-acting insulin analogs approved by European regulators.
The Sanofi product references Danish diabetes care giant’s Novo Nordisk (NOV: N) NovoRapid (insulin aspart), which generated sales of 4.7 billion kroner ($706 million) in the first quarter of 2020.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze